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Both metabolic syndrome (MetS) and chronic kidney disease (CKD) are major global health issues. Current clinical markers used
to reﬂect renal injury include albuminuria and estimated glomerular ﬁltration rate (eGFR). Given the same eGFR level, urine
albumin might be a better risk marker to predict progression of CKD and future development of cardiovascular diseases (CVDs).
SerumCystatinCisemergingasanewbiomarkerforearlydetection ofrenalinjuryassociatedwithMetSandcardiovascularrisk.In
addition to each component,MetS per se inﬂuences the incidence and prognosis ofrenal injury andthe odds ratios increased with
the increase in the number of metabolic abnormalities. Hyperinsulinemia, activation of rennin-angiotensin-aldosterone system,
increase of oxidative stress, and inﬂammatory cytokines are proposed to be the plausible biological link between MetS and CKD.
Weight control, stick control of blood pressure, glucose, and lipids disorders may lead to lessening renal injury and even the
subsequent CVD.
1.Introduction
MetS, a complicated clinicopathological entity with clus-
tering of CVD and metabolic risk factors, includes central
obesity, hypertension, dyslipidemia, and glucose intolerance.
Ithas beenpervasively recognized thatindividuals with MetS
are associated with the increased risks of type 2 diabetes and
CVD [1–3]. Abdominal fat plays an important role in MetS,
because it is predictive of sensitivity to insulin [4, 5]. It has
been reported that obesity adversely aﬀects renal function
and may be associated with morbidity and mortality in
patients with CKD [4]. Recent evidence also indicated that
presence of MetS is associated with an increased risk of
developing CKD [6, 7]. As a matter of fact, both MetS
and CKD are major global health issues with regard to the
increasing prevalence of obesity and aging society [8–11].
What is more alarming is the fact that the prevalence of end-
stage renal disease has more than doubled in the recent ten
years [9]. Although the relationship between MetS and CKD
was established, the detailed understanding of quantitative
association between MetS and its components implicated in
kidney damage is still limited. In this paper, we will review
the following issues:
(1) epidemiological association between MetS and CKD
incidence and/or progression,
(2) reliable markers of MetS associated with renal injury,
(3) plausible biologic links between MetS and CKD,
(4) impact of treating theMetS onthe risk of renal injury
or CKD progress.
2.EpidemiologicalAssociationbetween
MetS and CKDIncidenceand/orProgression
The association between MetS and CKD in diﬀerent pop-
ulations varies with odds ratio (OR) ranging from 0.93 to
2.60 according to our review (Table 1). In a group of 118,924
nondiabetic Chinese patients with a mean followup for 3.7
years, Sun et al. reported that multivariable adjusted HR
for CKD in subjects with MetS (ATP-III-MetS) was 1.30
(95%CI, 1.24–1.36)and 1.37(95%CI,1.30–1.44),evaluated2 Cardiology Research and Practice
by proteinuria and eGFR, respectively [12]. In American
Indians without diabetes, it is reported that adjusted hazard
ratio for incident CKD (measured by using eGFR and
urinary albumin-creatinine ratio) was 1.3 (95% CI, 1.1–1.6)
[7]. In a survey conducted in nondiabetic native Americans
(theintertribal heart project),the MetSwas associated witha
twofold increase on prevalence of microalbuminuria [13]. In
The Third National Health and Nutrition Examination Sur-
vey (NHANES III), independent excess risks for CKD were
hypertension, low HDL cholesterol, hypertriglyceridaemia,
fasting hyperglycemia, and large waist circumference after
adjustment for several confounding factors [14]. Notably,
the ORs of CKD (eGFR < 60mL/min per 1.73m2)w e r e
2.60 (95% CI, 1.68–4.03) and 1.89 (95% CI, 1.34–2.67)
in patients with or without MetS, respectively. This study
also found that even mildly elevated blood pressure or mild
hyperglycemia may portend an increased risk of CKD and
microalbuminuria. Remarkablely, high blood pressure was
the most powerful predictor of CKD in patients with MetS
and with the OR of 2.66 (95% CI, 1.62–4.35) [14, 15]. In
Atherosclerosis Risk in Communities (ARIC) study, a 9-
year follow-up survey of 10,096 nondiabetic patients, the
OR was 1.43 (95% CI, 1.18–1.73) for the development of
CKD in subjects with MetS [16]. Furthermore, the OR was
1.24 (95% CI, 1.01–1.51) even after being adjusted for the
subsequent development of diabetes and hypertension [16].
Accordingly, it is suggested that diabetes and hypertension
were responsible for the renal injury progress. In addition,
previous studies also suggested that dyslipidemia may also
aﬀect the prognosis of CKD [17–20]. Observations in the
Modiﬁcation Diet Renal Disease (MDRD) cohort indicated
that low high-density lipoprotein (HDL)cholesterol predicts
faster CKD progression [14, 21].
The ﬁndings of several previous studies conducted
diﬀerent ethnicities have that MetS per se aﬀected CKD. A
population-based study of native American adults resulted
in multivariate-adjusted ORs of CKD for patients with 0
or 1 component of the MetS; patients with 2, 3, 4, and
5 components of CKD had multivariate-adjusted ORs of
2.21 (CI, 1.16 to 4.24), 3.38 (CI, 1.48 to 7.69), 4.23 (CI,
2.06 to 8.63), and 5.85 (CI, 3.11 to 11.0), respectively.
The corresponding multivariate-adjusted ORs of microal-
buminuria for patients with 3, 4, and 5 components were
1.62 (CI, 1.10 to 2.38), 2.45 (CI, 1.55 to 3.85), and 3.19
(CI, 1.96 to 5.19), respectively [14]. Another study in the
US showed that the OR for microalbuminuria was 1.8 for
one MetS component, 1.8 (95% CI, 1.0 to 3.2) for two
components, and 2.3 (95% CI, 1.1 to 4.9) for three or more
components (versus no traits) after controlling age, sex,
smoking, body mass index, education, and family histories
of diabetes and kidney disease [13]. A cross-sectional survey
ofChineseadultsresultedthatthemultivariate-adjustedORs
(95% CI) of CKD in participants with and without the
MetS were 1.64 (1.16–2.32) and 1.36 (1.07–1.73). Compared
to participants without any component of the MetS, the
multivariate-adjusted ORs(95%CI)ofCKDwere 1.51(1.02,
2.23),1.50(0.97,2.32),2.13(1.30,3.50),and2.72(1.50,4.93)
for those with 1, 2, 3, and 4 or 5 components, respectively.
The corresponding multivariate-adjusted ORs (95% CI) of
elevated serum creatinine were 1.11 (0.88, 1.40), 1.39 (1.07,
2.04), 1.47 (1.06, 2.04), and 2.00 (1.32, 3.03), respectively
[26].
In summary, high blood pressure and hyperglycemia
seem to be the most powerful predictors of CKD in subjects
with MetS. Several population-based studies supported the
eﬀect of MetS on CKD evenafter adjusting for the inﬂuences
of diabetes and hypertension. Although the ORs of renal
injury in diﬀerent ethnicities were varied widely (Table 1),
all these results suggested that OR was higher in patients
with MetS than those without even adjusting for age and
gender. Furthermore, previous studies also suggested that
the ORs of renal injury increased with the increase in the
number of metabolic abnormalities, and the ﬁndings seem
to be independent of ethnicity. These ﬁndings suggest that
MetS per se is an important causative factor for CKD.
3.ReliableMarkersof theRenalInjury
3.1. The Deﬁnitions of Metabolic Syndrome. In 1988, “Syn-
drome X” was introduced by Reaven, who proposed that
insulin resistance plays a crucial role in glucose intolerance,
hyperinsulinemia, hypertension, increased plasma triglyc-
eride (TG), and decreased HDL cholesterol, all of which
are associated with atherosclerosis and increased risk of
coronary artery disease [1, 33]. The potential causes of
insulin resistance include the unhealthy life style, obesity,
and male,genetic,and environmental factors [34–37].World
HealthOrganization (WHO)designatedtheclusteringofthe
cardiovascular and metabolic risk factors as “MetS” [38].
Other diagnostic criteria of MetS include National Choles-
terol Education Program Adult Treatment Panel (NCEP-
ATP III) [2, 39] and International Diabetes Federation (IDF)
[40]. Each diagnostic criterion has its essential criteria,
for example, central obesity is a prerequisite for the MetS
according to the IDF criteria, but microalbuminuria is
considered a criterion only by the WHO. Recently, a cross-
sectional epidemiological study of Taiwan population had
reported that the adjusted ORs of microalbuminuria based
onﬁve diﬀerent deﬁnitionsof MetSare varied (Table 2)[ 41].
Insulin resistance is considered to be the key mechanism of
MetS [1, 42–44], but it is diﬃcult to be quantiﬁed. In order
to increase predictive power, some experts suggest that more
related biomarkers may be needed, such as high-sensitivity
C-reactiveprotein,uric acid,andotherinﬂammation marker
[36, 45–48].
3.2. The Reliable Markers of the Renal Injury. In general,
biomarkers are used for diagnosis, severity classiﬁcation,
and outcome prediction. We will discuss two traditional
biomarkers, eGFR and urine albumin, and one new marker
serumcystatinC[6,7,9,14,23,27,50–55].Which ofthemis
the most reliable and powerful marker in evaluating patients
with MetS remains controversial.
3.2.1. eGFR. Among individuals with CKD, the stages are
deﬁned based on the level of GFR, which is estimated by a
formula based on the value of creatinine [56]. CKD sharesCardiology Research and Practice 3
Table 1: OR of CKD in MetS: population-based studies.
(a)
Study Odds ratio
1. Hoehner et al. Americans  2002 [13] 2.3 1.1
1.1
1.68
4.9
4.03
1.51
2.07
3.52
1.85
1.32
2.66
1.92
2.41
3.94
2.13
1.6
1.54
2.49
1.01
1.13
1.23
1.28
1.16
1.49
0.45
1.43
1.05
1.1
1
1.12
1.34
1.24
1.30
0
1.37
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
1.3
1.83
1.31
1.3
1.53
2.03
1.86
0.93
1.99
1.64
1.54
2.08
1.53
1.24
2.6
2.3
1.8
12345
1.44
1.36
2. Chen et al. American adults 2004 [14] 
3. Kurella et al. American 2005 [22]
4. Choi et al. Korean 2006 [23]
5. Ninomiya et al. Japanese 2006 [24]
6. Tanaka et al. Japanese 2006 [25]
8. Hao et al. Japanese 2007 [27] 
9. Rashidi et al. American 2007 [28]
10.Tozawa et al. Japanese 2007 [29] 
11. Zhang et al. Chinese 2007 [30]
12. Kawamoto et al. Japanese 2008 [31]
13. Lucove et al. American Indians 2008 [7]
14. Luk et al. Hong Kong 2008 [32] 
15. Ryu et al. Korean 2009 [17]
16. Sun et al. nondiabetics Taiwanese  2010 [12] 
95% CI 
(b)
Study Ethnicity Adjusted risk factors OR (95% CI)
(1) Hoehner et al.
2002 [13]
Americans
Age + 1.8 (1.1–2.3)∼2.3 (1.1–4.9)
diﬀerence insulin resistance syndrome trait
powerful traits
hypertension, impair fasting glucose
Sex +
HTN
DM
(2) Chen et al.
2004 [14] American adults
Age +
2.60 (1.68–4.03) Sex +
HTN
DM
(3) Kurella et al.
2005 [22] Americans
Age +
1.24 (1.01–1.51) Sex +
HTN +
DM +
(4) Choi et al.
2006 [23] Korean
Age +
1.53 (1.13–2.07)
Powerful traits
TG and waist circumference
Sex +
HTN +
DM
(5) Ninomiya et al.
2006 [24]
Japanese
Age +
2.08 (1.23–3.52) Sex +
HTN
DM4 Cardiology Research and Practice
(b) Continued.
Study Ethnicity Adjusted risk factors OR (95% CI)
(6) Tanaka et al.
2006 [25] Japanese
Age +
1.54 (1.28–1.85) Sex +
HTN
DM
(7) Chen et al.
2007 [26] Chinese adults
Age +
1.64 (1.16–1.32) Sex +
HTN
DM
(8) Hao et al.
2007 [27] Japanese
Age +
1.99 (1.49–2.66) Sex +
HTN
DM
(9) Rashidi et al.
2007 [28] Americans
Age +
0.93 (0.45–1.92) Sex +
HTN +
DM
(10) Tozawa et al.
2007 [29] Japanese
Age +
1.86 (1.43–2.41) Sex +
HTN
DM
(11) Zhang et al.
2007 [30] Chinese
Age +
2.03 (1.05–3.94) Sex +
HTN +
DM +
(12) Kawamoto et al.
2008 [31] Japanese
Age +
1.53 (1.1–2.13) Sex +
HTN +
DM +
(13) Lucove et al.
2008 [7] American Indians
Age +
1.3 (1.0–1.6) Sex +
HTN
DM
(14) Luk et al.
2008 [32] Hong Kong
Age + 1.31 (1.12–1.54)
Powerful traits
central obesity, hypertriglyceridemia,
hypertension, and low BMI were independent
predictors for CKD.
Sex +
HTN
DM
(15) Ryu et al.
2009 [17] Korean
Age + 1.83 (1.34–2.49)
Powerful traits
increased TG and LDL cholesterol levels were
associated with signiﬁcantlyincreased risk of CKD
Sex +
HTN +
DM +
(16) Sun et al.
2010 [12] nondiabetc Taiwanese
Age +
ATP-III-MetS1.3 (1.24–1.36)
IDF –MetS 1.37 (1.30–1.44)
Sex +
HTN +
DM +Cardiology Research and Practice 5
Table 2: Deﬁnitions of metabolic syndrome and adjusted ORs of associated microalbuminuria.
WHO 1998 [38] EGIR 1999 [49] NCEP ATP III 2001 [39] IDF 2005 [40] AHA 2005 [2]
Essential criteria
Deﬁnition of MetS
IFG, IGT, or IR
plus 2 of other 5
criteria
Insulin in top 25%
plus 2 of other 4
criteria
Any 3 of 5 criteria
listed below
Increased waist
plus any of 2 of other 4
criteria
Any 3 of 5
criteria
listed below
Abdominal obesity
(men/women)
Waist-to-hip ratio
>0.9/0.85
BMI > 30 (kg/m2)
Waist
￿ 94/80 Waist > 90/80
Men
≥94cm
(European)
≥90cm
(Chinese)
≥90cm
(South
Asian)
≥85cm
(Japanese)
Women
≥80cm
(European)
≥80cm
(Chinese)
≥80cm
(South
Asian)
≥90cm
(Japanese)
Waist
￿ 90/80
Triglycerides
(nmol/L)
￿1.7 or drug
treatment for this
lipid abnormality
>2.0 or drug
treatment for this
lipid abnormality
￿1.7 or drug
treatment for this
lipid abnormality
￿1.7 or drug treatment
for this lipid
abnormality
￿1.7 or drug
treatment for
this lipid
abnormality
HDL cholesterol
(nmol/L)
(men/women)
<0.9/1.0 or drug
treatment for this
lipid abnormality
<1.0 or drug
treatment for this
lipid abnormality
<1.0/1.3 or drug
treatment for this
lipid abnormality
<1.0/1.3 or drug
treatment for this lipid
abnormality
<1.0/1.3 or
drug treatment
for
this lipid
abnormality
Blood pressure
(mmHg)
More than 140/90
or drug treatment
for hypertension
More than 140/90
or drug treatment
for hypertension
More than 130/85
or drug treatment
for hypertension
More than 130/85 or
drug treatment for
hypertension
More than
130/85 or drug
treatment for
hypertension
Fasting glucose
(nmol/L)
More than 6.1
HOMA-IR >2.53 More than 6.1 More than 6.1 More than 5.6 More than 5.6
Urinary albumin
excretion
More than 30mg/g
creatinine —— — —
Adjusted ORs
(95% CI) of
microalbuminuria
[41]
Men
4.44∗∗∗
(2.85–
6.91)
Women
4.16∗∗∗
(2.57–
6.73)
Men
2.62∗∗∗
(1.49–
4.60)
Women
1.80
(0.99–
3.29)
Men
1.99
(1.31–
3.03)
Women
2.21∗∗∗
(1.47–
3.32)
Men
1.51
(0.97–2.35)
Women
2.29∗∗∗
(1.51–3.48)
Men
1.64∗
(1.08–
2.50)
Women
2.26∗∗∗
(1.52–
3.38)
World Health Organization (WHO), European Group for the Study of Insulin Resistance (EGIR), National Cholesterol Education Program (NCEP),
Adult Treatment Panel III (ATP-III), International Diabetes Federation (IDF), American Heart Association and National Heart Lung and Blood Institute
(AHA/NHLBI), Metabolic Syndrome (MetS); Body mass index (BMI); high-density lipoprotein (HDL); homeostasis model assessment of insulin resistance
(HOMA-IR); insulin resistance (IR). Adjusted OR (95% CI) of microalbuminuria: a cross-sectional epidemiological study based on data from the Taichung
CommunityHealth Study[41]. ∗P<. 05; ∗∗P<. 01; ∗∗∗P<. 001.
many of the same risk factors as CVD, namely obesity
[9, 57], high blood pressure [58–60], diabetes mellitus [51,
58], hypertriglyceridemia [61], low HDL level [18, 20, 51],
and smoking [51]. These factors overlap with components
of MetS [51]. Direct measurement of GFR value may be
t h em o s tr e l i a b l em e a s u r eo fr e n a lf u n c t i o n .H o w e v e r ,t h e
obesity-relatedrenalinjuryisalsoassociatedwithglomerular
hyperperfusion, hyperﬁltration and causes slightly increases
of GFR [9, 55].
3.2.2. Urine Albumin. Albuminuria is generally conceived
as an attractive marker of MetS-related renal injury [6,
50]. According to the previous study, it is a better risk
marker than low estimated GFR to identify individuals at
risk for accelerated GFR loss [62]a n de v e nat a r g e tt o
improve cardiovascular and renal outcomes [63]. But some
limitations should be noted in evaluation about the urinary
albumin excretion for it would be aﬀected by infection,
stress condition and needed to be repeatedly measured. In
addition, while end-stage renal disease causes the reduction
of urine volume, albuminuria may no longer be increased
with renal function progression.
3.2.3. Cystatin C. Cystatin C is suggested to be a new
biomarker for the early detection of acute renal injury,
MetS, and cardiovascular risk [52–55, 64–66]. According
to the results of the Chennai Urban Rural Epidemiol-
ogy Study (CURES) (MetS was deﬁned using National
Cholesterol Education Program criteria for adults modiﬁed
for waist measured using the World Health Organization
Asia Paciﬁc guidelines. Serum cystin-C was estimated by
a high-sensitivity particle-enhancing nephelometry assay),6 Cardiology Research and Practice
it showed that subjects with four or ﬁve metabolic abnor-
malities had the highest cystatin C level. With decreasing
number of metabolic abnormalities, the cystatin C levels
decreased linearly (P for trend <.001), and it concluded
that Cystatin C levels are highly correlated with the number
of metabolic abnormalities in Asian Indians [67]. Previous
evidence suggested that the measurement of serum cystatin
C may be useful for evaluating cardiovascular risk proﬁle
[54]. A study reported that the association of cystatin C
level with all-cause and CVD mortality is even stronger than
that of GFR with these outcomes in stage 3 or 4 CKD [66].
Furthermore, cystatin C is considered to be a marker of
inﬂammation as well as renal function [64]. Among elderly
persons without CKD, cystatin C is a prognostic biomarker
of risk for death, CVD and CKD, and seems to identify
a preclinical state of kidney dysfunction that cannot be
completely detected by measurement of serum creatinine or
eGFR [65]. However, more clinical studies will be required
to evaluate the clinical usefulness and cost eﬀectiveness as
compared with traditional markers.
4.PlausibleBiologic Links between
MetS and CKD
4.1. Hyperinsulinemia, Central Obesity, Hypertension,
Dyslipidemia (Figure 1)
4.1.1. Hyperinsulinemia. Hyperinsulinemia-related insulin
resistance is suspectedtobethemost important link between
obesity and other metabolic complications leading to renal
injury [9]. Insulin resistance and associated hyperinsuline-
miamayleadtorenalinvolvementandinjurythroughseveral
diﬀerent pathways. For example, activation of the renin-
angiotensin system (RAS) with elevated angiotensin II and
aldosterone, which subsequently aﬀect insulin/insulin-like
growth factor-1 signaling pathways, reactive oxygen species
formation to destroy endothelial function, would cause
the development of CVD [68]. Hyperinsulinemia causes
atherosclerosis through hyperglycemia and dyslipidemia
and endothelial dysfunction by inducing oxidative stress
and attenuating peroxisome proliferator-activated receptor
(PPAR) gamma, and the downregulation of peroxisome
proliferator-activated receptors (PPARs) was proved by sev-
eral studies in vivo [69, 70]. Adipokines and proinﬂamma-
tory cytokines play an important role in the regulation of
endovascular atherosclerosis [71].
4.1.2. Central Obesity. It is well known that patients with
atherosclerotic complications are at a higher risk of CKD.
Abdominal obesity is especially related to incident CKD
and mortality. Inﬂammatory genes and genes implicated
in insulin resistance are overly expressed in glomeruli of
patients with obesity-related nephropathy [34, 35, 72].
Adipose tissue is the source of a novel group of hormonally
activesubstancesknownasadipokines.Adipokinesincluding
IL-6, TNF-α, and plasminogen activator inhibitor-1 (PAI-
1) may cause tissue damage by a direct proinﬂammatory
mechanism or insulin resistance (some adipokines improve
insulin resistance, for example, leptin, adiponectin, and
Visfatin) (Table 3)[ 4, 73, 74] and can be translated into
inﬂammatory changes in the kidney [48, 71].
4.1.3. Hypertension. Hypertension cause, nephrosclerosis by
blood pressure-dependent and -independent mechanisms.
In addition, adipokines is implicated in hypertension and
sodium retention secondary to obesity because it potently
activates the sympathetic system, including sympathetic
activity in the kidney [21]. Because of the interference
with glomerular hemodynamics and with inﬂammatory
mechanisms, the RAS is of paramount importance in CKD
generation, and the angiotensin-II blockade signiﬁcantly
reduces cytokines and oxidative stress [75]. Reduced GFR
has been found in prehypertensive patients with high blood
pressure load as well as increased proteinuria, suggesting
that even mild elevated blood pressure puts patients at
risk of developing renal injury [19, 76–78]. Evidence of
relationship between hypertension and CKD is further
supported by several clinical studies. Hypertension seems
to be an important risk factor of CKD (detected by eGFR
and albuminuria) for the elders [78]. A recent study, using
NHANES 1999–2004 data (n = 15,332; age ≥ 20 years),
indicated that the eﬀects of CVD are less dramatic when
hypertension and diabetes are considered [79].
4.1.4. Dyslipidemia. Dyslipidemia is related to the incidence
and prognosis of CKD through the following mechanisms,
such as inﬂammation and increased oxidative stress, which
would cause endothelial damage and atherosclerosis diseases
[80–82]. The mechanisms discussed above are congruent
with some clinical evidences, for example, hypertriglyc-
eridemia isan independentrisk factor forCKD[61],and low
HDL cholesterol predicts CKD progression [21].
4.2. Impact of Treating the MetS on the Risk of Kidney
Injury or CKD Progress. The eﬀects of MetS treatments in
improving renaloutcomesremain largelyunexplored.Wetry
to discuss the eﬀects of the interventions in controlling MetS
components based on limited evidence (Figure 1).
The adjusted ORs of renal injury associated with
individual or multiple components of the MetS had ever
been investigated. A cross-sectional survey conducted in a
nationally representative sample of 15160 Chinese adults
showed that the adjusted ORs of CKD with hypertension,
impaired fasting glucose, waist >102cm in men or >88cm
in women, high triglyceride, low HDL cholesterol were 1.17
(CI, 0.88 to 1.56), 1.93 (CI, 1.40 to 2.76), 1.95 (CI, 1.21 to
3.14), 0.92 (CI, 0.68 to 1.24), and 1.34 (CI, 0.98 to 1.83), and
theORs of renal injury increased with increasing the number
of metabolic abnormalities [26].
4.2.1. Hyperglycemia. It is widely recognized that intensive
treatment of hyperglycemia can signiﬁcantly delay the onset
of albuminuria and decrease the risk of diabetic CKD
[83–85]. Some evidences about using insulin sensitizer
(e.g., Thiazolidinedione and Metformin) suggested thatCardiology Research and Practice 7
Genetic factors
environmental
factors
Hyperinsulinemia Central
obesity Oxidative stress
Renal cell growth
PPARs
RAS activity
SNS activity
Urine albumin excretion
Endovascular disease
Tubular interstitial ﬁbrosis
Hypertension
Hyperglycemia
Inﬂammation
Dyslipidemia
ACEI
ARB
Statin
Fibrate
Statin
Fibrate Statin
Fibrate
TZD
TZD
Exercise
Diet
Operation
ACEI ARB
ACEI
ARB
Renal injury:
Control BP
Control sugar
Insulin sensitizer
Weight reduction
Control sugar,
lipid and BP
Control BP
Glomerulosclerosis
Metformin
Metformin
TZD Fibrate
Figure 1: Mechanisms of insulin resistance with the consequent development of renal injury and the target of treatments. SNS: sympathetic
nervous system, RAS: renin-angiotensin system, PPAR: peroxisome proliferator-activated receptors, ACEI: angiotensin-converting enzyme
inhibitor, ARB: angiotensin II receptor blocker, TZD: thiazolidinediones.
improving endothelial function may be beneﬁcial to renal
injury [86, 87].
4.2.2. Obesity. Exercise improves insulin resistance, values
of TG, HDL cholesterol, and blood pressure in patients
with the MetS. A cross-sectional analysis showed that
reducedrenalfunctioncorrelatedwithlowerphysicalactivity
[88], and previous evidence reported the improvement of
microalbuminuria after intense exercise in patients with
MetS [89]. Dietary changes are as follows: a low-calorie
diet can improve CKD while high protein intake may
worsen proteinuria and induce renal injury [90]. Antiobesity
drugs. Orlistat blocks intestinal lipase and produces modest
weight loss; it did not show obvious improvment on serum
creatinine in 3 months of continuous study [91]. Sibu-
tramine is a serotonin-norepinephrine reuptake inhibitor;
it may improve insulin sensitivity [92], but a previous
study reported that sibutramine exhibited weight loss and
reductions of cystatin C levels at 6 months, while serum
creatinine levels were not reduced [93]. It has a warning
on its label from the US Food and Drug Administration
because of cardiovascular risk. Surgical treatment includes a
variety of procedures performed on people who are obese,8 Cardiology Research and Practice
Table 3: The Adipokines eﬀect on insulin sensitivity.
Adipokines
(Adipose-derived
protein)
Eﬀect on insulin
sensitivity [73] Clinical signiﬁcance in CKD [4, 74]
Resistin Decline
Elevated serum levels
Similarlevels in both HD and PD
Associated to heart disease in dialysis [4]
TNF-α Decline
Elevated serum level
E n h a n c eg e n ee x p r e s s i o no fT N F - α in circulating blood cells in uraemia
Elevated TNF-α associated to increased mortality in HD
Anorexia and a poor nutritional status in PD [4]
IL-6 Decline
Elevated serum levels
Reliable predictor of mortality
Better mortality predictor than TNF-α in CKD and HD [4]
PAI-1 Decline
Elevated serum level
PlasmaPAI-1 levels increase in several chronic inﬂammatory states that are associated
withCKD
It may contribute to the pathogenesis of the accelerated vascular disease in this patient
population [74]
Leptin Improvement
Markedly elevated serum level
Clinical marker of body fat content in dialysis
Associated to inﬂammation,atherogenic lipid proﬁle, and insulin resistance in CKD
Low leptin is an independent risk factor for mortality in HD [4]
Adiponectin Improvement
Elevated serum level
Inversely associated with metabolic risk factors in uremia
Inversely associated with CV events in HD
Improved survival and better outcome in dialysis patients [4]
Visfatin Improvement
Elevated serum level
Anorexigenic
Decreased circulating levels of amino acids and triacylglycerols
Mortality predictor in CKD [4]
IL-6: interleukin-6, PAI-1: plasminogen activator inhibitor-1, TNF-α: tumor necrosis factor-alpha, HD: hemodialysis, PD: peritoneal dialysis.
reducing the size of the stomach with an implanted gastric
banding or sleeve gastrectomy or biliopancreatic diversion
with duodenal switch or gastric bypass surgery. Bariatric
surgery may achieve long-term weight loss in patients with
morbid obesity, improve the MetS, and reduce mortality,
but the prevalence of microalbuminuria after surgery was
only reduced in the diabetic group [91]. Reduction in
albuminuria associated with improvement in glomerular
hyperﬁltration after gastroplasty has been reported [94].
However,weshouldnoticetheseriouscomplications,suchas
oxalate nephropathy and nephrolithiasis, following bariatric
surgery.Therefore,bothsurgicalandnonsurgicalapproaches
appear to be eﬀective at reducing blood pressure and
proteinuria [95]. A meta-analysis including thirteen studies
reported that in smaller, short-duration studies in patients
with CKD, nonsurgical weight loss interventions reduce
proteinuria and blood pressure and prevent further decline
in renal function; while in morbidly obese patients with
glomerular hyperﬁltration, surgical interventions normalize
GFR and reduce blood pressure and microalbuminuria [96].
4.2.3. Hypertension. Blood pressure control helps in reduc-
ing CVD risk and CKD progression [97–101]. A continuous
study of 8.8 to 12.2 years stint in evaluating the progression
of CKD, which was deﬁned as a doubling of the serum crea-
tinine level, a diagnosis of end-stage renal disease, or death,
and showed that intensive blood-pressure control (the mean
blood pressure was 130/78mmHg in the intensive-control
group and 141/86mmHg in the standard-control group)
had no eﬀect on kidney disease progression but may lead
to diﬀerential eﬀects on intensive blood-pressure control in
patients with and those without baseline proteinuria [100].
Diﬀerent antihypertensive drugs may have diﬀerent eﬀects
on the protection of CKD [101]. Angiotension II signaling
and subsequent oxidative stress in adipose tissue may be
potential targets for the prevention of atherosclerotic cardio-
vascular disease in MetS and also in metabolic syndrome-
based CKD [75], and a previous study reported that the
Angiotensin-converting enzyme inhibitors (ACEIs) appear
to be more eﬀective than beta blockers or dihydropyridine
calcium channel blockers in slowing GFR decline [101].
ACEI is recommended for the treatment of hypertension in
patients with CKD and is considered a prognostic factor of
CKD [102]. Previous evidences suggested that angiotensin-
receptor blockers (ARBs) could reduce proteinuria, but the
results are variable. A study provided that ARB inhibits
albumin-elicited proximal tubular cell apoptosis and injury
invitro [103].Ameta-analysis fromJanuary 1990toSeptem-
ber2006 also reported thatthe ARBsreduce proteinuria, andCardiology Research and Practice 9
the reduction in proteinuria from ARB and ACEI is similar
[104].
4.2.4. Dyslipidemia. Fibrate therapy can decrease TG,
increase HDL cholesterol, improve insulin sensitivity, and
reduce the mesangium-induced glumerular matrix deposi-
tion [105]. Statin therapy can decrease LDL, TG, reduce
inﬂammation, and improve endothelial function [106–109].
The current data are based on eﬀects of proteinuria [110].
5.RelationshipbetweenMetS,Renal
Injury,and CVD
It is known that CKD is associated with decreased cardiac
function, ventricular hypertrophy, diastolic dysfunction, and
increased risk of adverse cardiovascular events [111]. The
components of MetS may contribute to the pathophysi-
ological interactions between heart and kidney in type 4
cardiorenal syndrome and cause subsequent cardiac damage
(traditional risk factors are diabetes, hypertension, low
HDL cholesterol, and physical inactivity; nontraditional risk
factors are albuminuria, oxidative stress, or high sympathetic
tone) [111, 112]. A recent study reported the association
between MetS, CKD, and left ventricular hypertrophy (LVH)
and suspected that the combination of MetS and CKD is
a strong risk for LVH as well as a strong and independent
predictorofsubsequentCVD[113].Furthermore,aprevious
study indicated that the coexistence of early CKD with MetS
could increase the accuracy of risk prediction for CVD
mortality [114].
6.Conclusions
In addition to the eﬀect of diabetes and hypertension, MetS
is related to the incidence and prognosis of renal injury
and CKD. MetS-associated renal injury may predict the
subsequent CVD and even the mortality. Further studies
about the MetS components that are implicated in renal
damage can help to establish the targets in intervention of
MetS in order to prevent CKD and CVD.
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